Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $25.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 233.33% from the stock’s previous close.
A number of other research analysts have also commented on ORIC. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Tuesday, April 21st. Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 price objective on shares of Oric Pharmaceuticals in a report on Tuesday, February 24th. Citigroup decreased their price objective on Oric Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Tuesday, May 5th. Wedbush decreased their price objective on Oric Pharmaceuticals from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Wednesday, April 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Oric Pharmaceuticals in a report on Friday, May 22nd. Twelve research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.36.
Read Our Latest Stock Report on ORIC
Oric Pharmaceuticals Stock Performance
Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.03). As a group, sell-side analysts predict that Oric Pharmaceuticals will post -1.43 EPS for the current fiscal year.
Institutional Trading of Oric Pharmaceuticals
Several institutional investors and hedge funds have recently modified their holdings of ORIC. Mirae Asset Global Investments Co. Ltd. raised its position in Oric Pharmaceuticals by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company’s stock valued at $39,000 after purchasing an additional 977 shares during the last quarter. California State Teachers Retirement System raised its position in Oric Pharmaceuticals by 3.9% in the fourth quarter. California State Teachers Retirement System now owns 33,959 shares of the company’s stock valued at $278,000 after purchasing an additional 1,270 shares during the last quarter. ProShare Advisors LLC raised its position in Oric Pharmaceuticals by 12.9% in the third quarter. ProShare Advisors LLC now owns 13,383 shares of the company’s stock valued at $161,000 after purchasing an additional 1,527 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Oric Pharmaceuticals by 1.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 128,649 shares of the company’s stock valued at $1,042,000 after purchasing an additional 1,985 shares during the last quarter. Finally, Federation des caisses Desjardins du Quebec raised its position in Oric Pharmaceuticals by 100.0% in the fourth quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company’s stock valued at $33,000 after purchasing an additional 2,000 shares during the last quarter. 95.05% of the stock is currently owned by institutional investors.
About Oric Pharmaceuticals
Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.
The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.
Featured Articles
- Five stocks we like better than Oric Pharmaceuticals
- 3 Longevity ETFs to Buy and Hold (and Hold)
- The Market May Be Missing What’s Changing at BigBear AI
- These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?
- 3 Stocks Under $20 to Buy Before a Broader Market Rally
Receive News & Ratings for Oric Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oric Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
